---
title: "Ionis Pharma | 8-K: FY2025 Q2 Revenue Beats Estimate at USD 452 M"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/250826157.md"
published_at: "2025-07-30T15:17:41.000Z"
---

# Ionis Pharma | 8-K: FY2025 Q2 Revenue Beats Estimate at USD 452 M

Revenue: As of FY2025 Q2, the actual value is USD 452 M, beating the estimate of USD 298.99 M.

EPS: As of FY2025 Q2, the actual value is USD 0.7, beating the estimate of USD -0.0908.

EBIT: As of FY2025 Q2, the actual value is USD 140 M, beating the estimate of USD -14.86 M.

### Segment Revenue

-   **TRYNGOLZA Sales**: $19 million in net product sales in the second quarter of 2025 and $26 million in the first half of 2025.
-   **Total Revenue**: $452 million for the second quarter of 2025, compared to $225 million in the same period of 2024; $584 million for the first half of 2025, compared to $345 million in the same period of 2024.

### Operational Metrics

-   **Operating Expenses**: $312 million for the second quarter of 2025, compared to $291 million in the same period of 2024; $591 million for the first half of 2025, compared to $560 million in the same period of 2024.
-   **Income (Loss) from Operations**: $140 million for the second quarter of 2025, compared to -$66 million in the same period of 2024; -$7 million for the first half of 2025, compared to -$215 million in the same period of 2024.
-   **Net Income (Loss)**: $124 million for the second quarter of 2025, compared to -$66 million in the same period of 2024; -$23 million for the first half of 2025, compared to -$209 million in the same period of 2024.

### Cash Flow

-   **Cash, Cash Equivalents, and Short-term Investments**: $2.3 billion as of June 30, 2025, consistent with December 31, 2024.

### Unique Metrics

-   **Royalty Revenue**: $70 million for the second quarter of 2025, compared to $64 million in the same period of 2024; $134 million for the first half of 2025, compared to $113 million in the same period of 2024.

### Outlook / Guidance

-   Ionis Pharmaceuticals, Inc. has increased its 2025 financial guidance, projecting total revenue between $825-850 million, up from the previous guidance of $725-750 million, driven by strong performance and improved outlook. TRYNGOLZA product sales are expected to reach $75-80 million. The company anticipates achieving sustained growth and positive cash flow in the next few years, supported by multiple independent launches and increasing royalty revenue.

### Related Stocks

- [IONS.US - Ionis Pharma](https://longbridge.com/en/quote/IONS.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Ionis to present at upcoming investor conferences \| IONS Stock News | Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) will participate in several upcoming investor conferences, including the Oppe | [Link](https://longbridge.com/en/news/276330201.md) |
| Ionis updates time for fourth quarter and full year 2025 financial results webcast \| IONS Stock News | Ionis Pharmaceuticals, Inc. has rescheduled its fourth quarter and full year 2025 financial results webcast to February  | [Link](https://longbridge.com/en/news/276162682.md) |
| Expert Outlook: Ionis Pharmaceuticals Through The Eyes Of 6 Analysts | In the latest quarter, 6 analysts provided mixed ratings for Ionis Pharmaceuticals (NASDAQ:IONS), with an average 12-mon | [Link](https://longbridge.com/en/news/275171994.md) |
| Ionis Pharmaceuticals: Underappreciated Bepirovirsen and Multiple Late-Stage Catalysts Support Buy Rating | William Blair analyst Myles Minter has reiterated a Buy rating on Ionis Pharmaceuticals (IONS) due to its promising late | [Link](https://longbridge.com/en/news/271790979.md) |
| Squarepoint Ops LLC Sells 170,978 Shares of Ionis Pharmaceuticals, Inc. $IONS | Squarepoint Ops LLC reduced its holdings in Ionis Pharmaceuticals by 56% in Q2, selling 170,978 shares. The firm now own | [Link](https://longbridge.com/en/news/269716130.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.